Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) is reporting second quarter financial results on Wednesday 12th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, CYCC is expected to report 2Q20 loss of $ 0.47 per share.
For the full year, analysts anticipate loss of $ 2.54 per share bottom line.
Previous Quarter Performance
Cyclacel Pharmaceuticals, Inc. outlined loss for the first quarter of $ 1.48 per share, from the revenue of . The quarterly earnings compared with the same quarter last year. According to street consensus, loss of $ 2.90 was expected per share The bottom line results beat street analysts by $ 1.42 or 48.97 percent, at the same time, top line results analysts by $ 100.20 million or .
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of CYCC was $ 4.66, representing a 21.04 % increase from the 52 week low of $ 3.85 and a 76.22 % decrease over the 52 week high of $ 19.60.
The company has a market capital of $ 22.65 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CYCC” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Cyclacel Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.cyclacel.com
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The companys oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia.
